<DOC>
	<DOCNO>NCT02787005</DOCNO>
	<brief_summary>This study pembrolizumab ( MK-3475 ) participant metastatic castration-resistant prostate cancer ( mCRPC ) previously treat docetaxel-based chemotherapy . Participants enrol one three cohort : Cohort 1 ( participant program cell death ligand 1 [ PD-L1 ] -positive , measurable disease ) , Cohort 2 ( participant PD-L1 negative , measurable disease ) , Cohort 3 ( participant bone-metastases non-measurable disease )</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Metastatic Castration-Resistant Prostate Cancer ( mCRPC ) Previously Treated With Chemotherapy ( MK-3475-199/KEYNOTE-199 )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has histologically cytologicallyconfirmed adenocarcinoma prostate without small cell histology . Disease must either metastatic locally confine inoperable disease treat definitive intent ( chance curative intervention ) . Has supply tumor tissue either newly obtain biopsy archival specimen site previously irradiate . Participants Cohorts 1 2 visceral/measurable lesion must provide newly obtain biopsy perform last line systemic therapy archival specimen , available . Participants Cohort 3 must provide archival specimen . Has treat : At least 1 targeted endocrine therapy ( defined second generation antiandrogen therapy include limited abiraterone acetate prednisone , enzalutamide , next generation target agent ARN509 ) . At least 1 regimen/line chemotherapy contain docetaxel . No 2 chemotherapy regimen . No 3 regimens/lines aforementioned treatment ( failed/progressed chemotherapy target endocrine therapy ) . Has document prostate cancer progression within 6 month prior screen , determine Investigator , mean one following : 1 ) PSA progression define minimum 3 rise PSA level interval ≥1 week assessment PSA value screen ≥2 ng/mL , OR , 2 ) Radiographic disease progression soft tissue bone without PSA progression Has ongoing androgen deprivation total serum testosterone &lt; 50 ng/dL ( &lt; 2.0 nM ) . Participants receive bone resorptive therapy ( include limit bisphosphonate Receptor activator nuclear factor kappaB ligand [ RANKL inhibitor ] ) must stable dos ≥4 week prior first dose study drug . Has performance status 0 , 1 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Males reproductive potential must agree use adequate method contraception , start first dose study drug 120 day last dose study drug . Demonstrates adequate organ function . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigation device within 4 week first dose study drug . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior first dose study drug recover ( i.e. , ≤ Grade 1 Baseline ) adverse event due mAbs administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , external beam radiation therapy within 4 week prior first dose study drug recover ( i.e. , ≤ Grade 1 Baseline ) adverse event due previously administer agent . Has know additional malignancy progression require active treatment last 3 year . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use disease modify agent , corticosteroid immunosuppressive drug ) . Has evidence interstitial lung disease and/or history ( noninfectious ) pneumonitis require steroid , current pneumonitis . Has active infection require systemic therapy . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Has previously participate pembrolizumab ( MK3475 ) trial , receive prior therapy antiprogrammed cell death 1 ( antiPD1 , antiPD ligand 1 [ antiPDL1 ] , antiPDL2 [ include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ] ) . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B Hepatitis C. Has receive live vaccine within 30 day plan start study drug .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>